Search results
Results From The WOW.Com Content Network
Organon (OGN) delivered earnings and revenue surprises of 17.86% and 2.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Organon expects net leverage to be elevated above 4.0x due to the transaction. Price Action: At last check on Wednesday, OGN stock was down 2.14% at $20.11, while ROIV stock was down 0.08%. Read Next:
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. [4] Organon specializes in the following core therapeutic fields: reproductive medicine , contraception , psychiatry , hormone replacement therapy (HRT), and anesthesia .
A loss of just over 24 percent on May 5, 1893, from 39.90 to 30.02 signaled the apex of the stock effects of the Panic of 1893; the 2007–2008 crash was a 61.8 percent retracement thereof that began on October 11, 2007, and lasted until the closing low on March 9, 2009.
Will be right back... Thank you for your patience. Our engineers are working quickly to resolve the issue.
Organon (OGN) delivered earnings and revenue surprises of 7.76% and 5.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
In 2007 Organon International was sold to Schering-Plough for €11 billion and AkzoNobel delisted its shares from the US NASDAQ stock market. In 2008 Crown Paints was sold in a management buyout. [13] In December 2012, AkzoNobel agrees to sell its North American Architectural Coatings business to PPG Industries for $1.1 billion. [14]
For premium support please call: 800-290-4726 more ways to reach us